E-LIB Suche - Ergebnisse für: Emilie Clay

1

Cost-Effectiveness Analysis of Innovative Therapies for Pat..:

Pochopien, Michal ; Dziedzic, Jakub Wladyslaw ; Aballea, Samuel...
Journal of Market Access & Health Policy. 12 (2024) 2 - p. 35-57 , 2024

Link: https://doi.org/10.3390/..

2

Assessing the validity of a rapid review against a systemat..:

Smela, Beata ; Toumi, Mondher ; Świerk, Karolina...
Journal of Epidemiology and Population Health. 72 (2024) 4 - p. 202526 , 2024

Link: https://doi.org/10.1016/..

3

Systematic literature reviews over the years:

Smela, Beata ; Toumi, Mondher ; Świerk, Karolina...
Journal of Market Access & Health Policy. 11 (2023) 1 - p. , 2023

Link: https://doi.org/10.1080/..

4

Rapid literature review: definition and methodology:

Smela, Beata ; Toumi, Mondher ; Świerk, Karolina...
Journal of Market Access & Health Policy. 11 (2023) 1 - p. , 2023

Link: https://doi.org/10.1080/..

5

Economic evaluation of encorafenib with cetuximab in patien..:

Trouiller, Jean-Baptiste ; Macabeo, Bérengère ; Poll, Andrew...
BMJ Open. 12 (2022) 11 - p. e063700 , 2022

Link: https://doi.org/10.1136/..

6

Allocating treatment resources for hepatitis C in the UK: a..:

Han, Ru ; Liang, Shuyao ; François, Clément...
Journal of Market Access & Health Policy. 9 (2021) 1 - p. , 2021

Link: https://doi.org/10.1080/..

7

An overview of health technology assessments of gene therap..:

Pochopień, Michał ; Paterak, Ewelina ; Clay, Emilie...
Journal of Market Access & Health Policy. 9 (2021) 1 - p. , 2021

Link: https://doi.org/10.1080/..

8

Efficacy and Safety of Rivaroxaban Compared with Other Ther..:

Bauersachs, Rupert ; Wu, Olivia ; Hawkins, Neil...
Cardiovascular Therapeutics. 2021 (2021) - p. 1-11 , 2021

Link: https://doi.org/10.1155/..

9

Real-world cost-effectiveness of rivaroxaban compared with ..:

Bowrin, Kevin ; Briere, Jean-Baptiste ; Fauchier, Laurent...
PLOS ONE. 15 (2020) 1 - p. e0225301 , 2020

Link: https://doi.org/10.1371/..

10

Cost-effectiveness of pirfenidone compared to all available..:

Clay, Emilie ; Cristeau, Olivier ; Chafaie, Romain...
Journal of Market Access & Health Policy. 7 (2019) 1 - p. 1626171 , 2019

Link: https://doi.org/10.1080/..

11

Cost-effectiveness analysis of pembrolizumab versus standar..:

Chouaid, Christos ; Bensimon, Lionel ; Clay, Emilie...
Lung Cancer. 127 (2019) - p. 44-52 , 2019

Link: https://doi.org/10.1016/..

12

Economic burden for Alzheimer's disease in China from 2010 ..:

Clay, Emilie ; Zhou, Junwen ; Yi, Zhan-Miao..
Journal of Market Access & Health Policy. 7 (2019) 1 - p. 1667195 , 2019

Link: https://doi.org/10.1080/..

13

Health related quality of life in patients having schizophr..:

Azaiez, Chiraz ; Millier, Aurélie ; Lançon, Christophe...
Journal of Market Access & Health Policy. 6 (2018) 1 - p. 1517573 , 2018

Link: https://doi.org/10.1080/..

14

Budget impact model of Mydrane®, a new intracameral injecta..:

Davey, Keith ; Chang, Bernard ; Purslow, Christine..
BMC Ophthalmology. 18 (2018) 1 - p. , 2018

Link: https://doi.org/10.1186/..

15

Cost-effectiveness of edoxaban compared to warfarin for the..:

Clay, Emilie ; Jamotte, Aurélien ; Verhamme, Peter...
Journal of Market Access & Health Policy. 6 (2018) 1 - p. 1495974 , 2018

Link: https://doi.org/10.1080/..